{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:41:43Z","timestamp":1793889703410,"version":"4.8.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eclinm.2025.103362","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T11:50:20Z","timestamp":1752925820000},"page":"103362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis"],"prefix":"10.1016","volume":"86","author":[{"given":"Poyee","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2025.103362_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103362_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1470-2045(12)70268-1","article-title":"Cancer transition and priorities for cancer control","volume":"13","author":"Maule","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103362_bib3","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103362_bib4","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2025.103362_bib5","series-title":"Cancer: disease control priorities","article-title":"The changing global burden of cancer: transitions in human development and implications for cancer prevention and control","author":"Bray","year":"2015"},{"issue":"10440","key":"10.1016\/j.eclinm.2025.103362_bib6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103362_bib7","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/ijms21072367","article-title":"Modern aspects of immunotherapy with checkpoint inhibitors in melanoma","volume":"21","author":"Petrova","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7637","key":"10.1016\/j.eclinm.2025.103362_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103362_bib9","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2174\/138920112800958913","article-title":"Oncolytic viruses for induction of anti-tumor immunity","volume":"13","author":"Tong","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2025.103362_bib11","first-page":"83","article-title":"Oncolytic viruses: do they have a role in anti-cancer therapy?","volume":"2","author":"Prestwich","year":"2008","journal-title":"Clin Med Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103362_bib12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103362_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bjc.2015.481","article-title":"Oncolytic viruses: finally delivering","volume":"114","author":"Seymour","year":"2016","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103362_bib14","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.molonc.2015.10.009","article-title":"Cancer immunotherapy: strategies for personalization and combinatorial approaches","volume":"9","author":"Sathyanarayanan","year":"2015","journal-title":"Mol Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103362_bib15","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ymthe.2017.03.026","article-title":"Oncolytic virotherapy: a contest between apples and oranges","volume":"25","author":"Russell","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103362_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11684-020-0750-4","article-title":"Development of oncolytic virotherapy: from genetic modification to combination therapy","volume":"14","author":"Lan","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.eclinm.2025.103362_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.omto.2019.09.006","article-title":"Syncytia formation in oncolytic virotherapy","volume":"15","author":"Burton","year":"2019","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103362_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103362_bib19","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.21037\/tcr-21-905","article-title":"The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis","volume":"10","author":"Gao","year":"2021","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12985-023-02220-x","article-title":"The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis","volume":"20","author":"Wang","year":"2023","journal-title":"Virol J"},{"key":"10.1016\/j.eclinm.2025.103362_bib21","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103362_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib23","doi-asserted-by":"crossref","DOI":"10.2202\/1557-4679.1103","article-title":"Exact calculations of average power for the Benjamini-Hochberg procedure","volume":"4","author":"Glueck","year":"2008","journal-title":"Int J Biostat"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"5","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.eclinm.2025.103362_bib25","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103362_bib26","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103362_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.eclinm.2025.103362_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103362_bib29","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5","author":"Higgins","year":"2024"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103362_bib30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7129","key":"10.1016\/j.eclinm.2025.103362_bib31","first-page":"470","article-title":"Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased","volume":"316","author":"Irwig","year":"1998","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.eclinm.2025.103362_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jid.2018.10.028","article-title":"Research techniques made simple: network meta-analysis","volume":"139","author":"Watt","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103362_bib34","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/aje\/153.12.1222","article-title":"Commentary: practical advantages of Bayesian analysis of epidemiologic data","volume":"153","author":"Dunson","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103362_bib35","first-page":"380","article-title":"Bayesian updating of stuctural models and reliability using Markov chain Monte Carlo simulation","volume":"128","author":"Beck","year":"2002","journal-title":"J Eng Mech"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103362_bib36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman","year":"1992","journal-title":"Stat Sci"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-208658","article-title":"Heterogeneity, consistency and model fit should be assessed in Bayesian network meta-analysis","volume":"75","author":"Wei","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103362_bib38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4097\/kja.21358","article-title":"Concepts and emerging issues of network meta-analysis","volume":"74","author":"Ahn","year":"2021","journal-title":"Korean J Anesthesiol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib39","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias","year":"2019","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103362_bib40","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity-subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103362_bib41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.eclinm.2025.103362_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"7-8","key":"10.1016\/j.eclinm.2025.103362_bib43","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103362_bib44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.eclinm.2025.103362_bib45","series-title":"NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials","author":"Dias","year":"2014"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103362_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103362_bib47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/biomedicines8030061","article-title":"Cancer vaccines and oncolytic viruses exert profoundly lower side effects in cancer patients than other systemic therapies: a comparative analysis","volume":"8","author":"Schirrmacher","year":"2020","journal-title":"Biomedicines"},{"issue":"7-8","key":"10.1016\/j.eclinm.2025.103362_bib48","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.addr.2009.03.013","article-title":"Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis","volume":"61","author":"Dorer","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103362_bib49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1200\/JCO.2006.08.9755","article-title":"Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma","volume":"25","author":"Taylor","year":"2007","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.eclinm.2025.103362_bib50","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.19.03205","article-title":"Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer","volume":"38","author":"Mlecnik","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.eclinm.2025.103362_bib51","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103362_bib52","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J Virol"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103362_bib53","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1128\/JVI.00545-07","article-title":"Cytokine-independent upregulation of MDA5 in viral infection","volume":"81","author":"Yount","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.eclinm.2025.103362_bib54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/OV.S143808","article-title":"Current understanding of reovirus oncolysis mechanisms","volume":"7","author":"Phillips","year":"2018","journal-title":"Oncolytic Virother"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103362_bib56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103362_bib57","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: first in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.eclinm.2025.103362_bib58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol Ther Oncolytics"},{"issue":"16","key":"10.1016\/j.eclinm.2025.103362_bib59","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMsb2300232","article-title":"Immune checkpoint inhibitors-the need for innovation","volume":"388","author":"Johnson","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103362_bib60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103362_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103362_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"10304","key":"10.1016\/j.eclinm.2025.103362_bib63","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103362_bib64","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: a review","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib66","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ijc.31301","article-title":"Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)","volume":"143","author":"Wu","year":"2018","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103362_bib68","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2025.103362_bib69","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103362_bib70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2025.103362_bib71","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103362_bib72","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103362_bib73","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103362_bib74","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103362_bib75","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gutjnl-2016-312009","article-title":"Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer","volume":"67","author":"Samson","year":"2018","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103362_bib76","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1586\/14737140.8.10.1581","article-title":"Oncolytic viruses: a novel form of immunotherapy","volume":"8","author":"Prestwich","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103362_bib77","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103362_bib78","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2010.159","article-title":"Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment","volume":"22","author":"Ausubel","year":"2011","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103362_bib79","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.eclinm.2025.103362_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1308890","article-title":"Oncolytic virotherapy in cancer treatment: challenges and optimization prospects","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103362_bib81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.eclinm.2025.103362_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"issue":"7129","key":"10.1016\/j.eclinm.2025.103362_bib83","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.316.7129.469","article-title":"Bias in meta-analysis detected by a simple, graphical test. asymmetry detected in funnel plot was probably due to true heterogeneity","volume":"316","author":"Stuck","year":"1998","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.eclinm.2025.103362_bib84","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103362_bib85","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2025.103362_bib86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-publhealth-051920-114020","article-title":"Methods to address confounding and other biases in meta-analyses: review and recommendations","volume":"43","author":"Mathur","year":"2022","journal-title":"Annu Rev Public Health"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103362_bib87","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1016\/j.eclinm.2025.103362_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d7762","article-title":"Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey","volume":"344","author":"Ahmed","year":"2012","journal-title":"BMJ"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:11:55Z","timestamp":1755850315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025002949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":88,"alternative-id":["S2589537025002949"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103362","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103362"}}